Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Compare
Equity
Direct
Sector - Healthcare

NAV: ₹ 17.1 as on 24-03-2023

Fund Performance
zero opening, trading, fund transfer fee
302 people have invested ₹ 7.2L in mutual fund in the last three months

Fund Insights

Insights icon

In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given -2.81% return, outperforming Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth by 8.23%

Insights icon

In the last 3 years, DSP Healthcare Fund Direct Growth has given 29.51% return, outperforming Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth by 8.08% per annum

Insights icon

Over the last 1 month, Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has increased expense ratio by 12.5% moving from 1.04 to 1.17

Insights icon

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.17% which is lower than the category average expense ratio of 1.67%

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.

Pros

Hold on while we find any good points for this fund.

Cons

3Y returns in the bottom 25% of the category

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Performance as on (24-Mar-23)

Return
1M
3M
6M
1Y
3Y
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
-2.1%
-7%
-4.3%
-11%
21.4%
Nifty 500
-1.9%
-7.4%
-3%
-2.5%
26.8%
sector - healthcare
-2%
-6.9%
-4.6%
-9.8%
24.5%

About the Fund

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on  11 July, 2019. The fund is managed by Dhaval Shah. The fund could potentially beat inflation in the long-run.

Key parameters

1) Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has a NAV of 17.08 as on 24-03-2023.

2) Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has 425 Cr worth of assets under management (AUM) as on 31-01-2023 and is less than category average.

3) The fund has an expense ratio 1.17 %.

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Overview

Expense ratio
Expense ratio
1.17%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹425 Cr
Inception Date
Inception Date
11 July, 2019
Min Lumpsum/SIP
Min Lumpsum/SIP
₹1000/₹500
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
64.89%

Fund Distribution as on (28-Feb-23)

  • Equity 94.3%

  • Debt & Cash 5.7%

Size breakup

Large cap
43.9%
Mid cap
25.3%
Small cap
25.1%

Sector Allocation

Feb'23

Jan'23

Dec'22

Health

97.6%

Basic Materials

1.3%

Consumer Defensive

1%

Top Holdings of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth as on (28-Feb-23)

  • Equity

Equity Holdings31

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth: Monthly Changes Updates

All changes are between Dec'22 and Feb'23

Fund Performance

Feb'23
Jan'23
Dec'22
Fund Returns
-2.54%
-2.64%
-3.86%
Nifty 500
-2.22%
-3.79%
-3.47%
  • This fund’s returns stands at -2.54% whereas the fund’s underlying benchmark Nifty 500 returns stands at -2.22% as on Feb'23
  • This fund underperformed Nifty 500 by 0.33% in Feb'23

AUM Change

Parameters
Feb'23
Jan'23
Dec'22
AUM
₹ 425.5 Cr
₹ 439.7 Cr
₹ 461.7 Cr
  • AUM of the fund stands at 425.5 Cr as of Feb'23
  • AUM decreased by 14.3 Cr between Feb'23 and Jan'23

Fund Portfolio Changes

Top Stocks bought last month
Sun Pharmaceuticals Industries Ltd's allocation increased from 16.97% to 18.03%
Sun Pharmaceuticals Industries Ltd's allocation increased from 16.97% to 18.03%
Dr Reddy's Laboratories Ltd's allocation increased from 6.85% to 7.34%
Dr Reddy's Laboratories Ltd's allocation increased from 6.85% to 7.34%
J.B. Chemicals & Pharmaceuticals Ltd's allocation increased from 2.88% to 3.17%
J.B. Chemicals & Pharmaceuticals Ltd's allocation increased from 2.88% to 3.17%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 9.64 % to 9.39 %
Cipla Ltd's allocation decreased from 9.64 % to 9.39 %
Apollo Hospitals Enterprise Ltd's allocation decreased from 9.11 % to 9.09 %
Apollo Hospitals Enterprise Ltd's allocation decreased from 9.11 % to 9.09 %
Indoco Remedies Ltd's allocation decreased from 3.25 % to 2.75 %
Indoco Remedies Ltd's allocation decreased from 3.25 % to 2.75 %
Small Cap allocation has gone up from 24.8% to 25.1%
Small Cap allocation has gone up from 24.8% to 25.1%
Mid Cap allocation has gone up from 23.2% to 25.3%
Mid Cap allocation has gone up from 23.2% to 25.3%
Large Cap allocation has gone down from 50.4% to 43.9%
Large Cap allocation has gone down from 50.4% to 43.9%
Cash allocation has gone up from 1.6% to 5.7%
Cash allocation has gone up from 1.6% to 5.7%

Top 3 Sectors in February were Health, Basic Materials & Consumer Defensive

Feb'23
Health
98%
Basic Materials
1%
Consumer Defensive
1%
Jan'23
Health
98%
Basic Materials
1%
Consumer Defensive

Gainers & Losers in Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth portfolio as on (28-Feb-23)

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Fund Manager

Dhaval Shah

Dhaval Shah

Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth, since 11 July 2019

Fund Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 15.4% since inception which is more than its category average return of 13.52%
Fund Allocations

Fund Allocations

This fund has an allocation of 94.34% in Equity, 0% in Debt and 5.66% in Cash related instruments
AUM size ₹425 Cr

AUM size ₹425 Cr

This fund has AUM of ₹425 Cr which is less than its category average of ₹ 1251 Cr
Expense Ratio 1.17%

Expense Ratio 1.17%

This fund has an expense ratio of 1.17% which is less than its category average expense ratio of 1.56%

Frequently Asked Questions

The current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is 17.16 as on 23-Mar-2023.
Existing (Absolute + CAGR)
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
-1.72%
-1.72%
6 Month Returns
-3.87%
-3.87%
1 Year Returns
-9.54%
-9.54%
3 Years Returns
82.36%
22.17%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.17 as on February 2023
425 Cr as on February 2023
Sun Pharmaceuticals Industries Ltd(17.23%),Apollo Hospitals Enterprise Ltd(9.72%),Dr Reddy's Laboratories Ltd(7.57%),Lupin Ltd(5.19%),Fortis Healthcare Ltd(5.07%) as on February 2023
Health(92.11%),Cash Equivalent(5.66%),Basic Materials(1.25%) as on February 2023
The alpha ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
0.48
-0.89
-
As on February 2023
The alpha for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
0.91
0.9
-
As on February 2023
The Beta for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
-0.79
0.59
-
As on February 2023
The sharpe ratio for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
12.62
20.53
-
As on February 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.15 as on February 2023. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Dhaval Shah is the fund manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The Exit load of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is 1%